Novartis India LimitedRegd. off: Sandoz House, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai 400 018

in`million STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2012								
	Particulars	3 months ended 31.12.2012	3 months ended 30.9.2012	3 months ended 31.12.2011	9 months ended 31.12.2012	9 months ended 31.12.2011	Year ended 31.3.2012	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1.	Income from Operations (a) Net Sales/Income from Operations (Net of Excise Duty)	2,335.4	2,374.3	2,223.2	6,904.9	6,414.2	8,442.8	
	(b) Other Operating Income	-	-	-	0.2	0.1	0.1	
	Total Income from Operations (Net)	2,335.4	2,374.3	2,223.2	6,905.1	6,414.3	8,442.9	
2.	Expenses (a) Cost of Materials Consumed (b) Purchases of Stock-in-Trade (c) Changes in Inventories To Hinshed Goods, Work-in-	96.6 855.9	110.9 992.9	83.6 737.4	276.4 2,666.2	230.0 2,163.1	313.9 3,023.8	
	Progress and Stock-in-Trade	9.1	(85.5)	5.5	(102.6)	(49.7)	(222.9)	
	(d) Employee Benefits Expense (e) Depreciation and Amortisation Expense	398.7 10.6	358.2 7.6	329.7 7.6	1,148.1 25.8	990.1 19.1	1,316.5 26.7	
	(f) Other Expenses	741.6	608.7	688.5	2,101.8	1,848.9	2,572.7	
	Total Expenses	2,112.5	1,992.8	1,852.3	6,115.7	5,201.5	7,030.7	
2	Profit from Operations before Other Income and	2/112.3	1/352.0	1,032.3	0/11317	3/201.3	7,030.7	
э.	Finance Costs	222.9	381.5	370.9	789.4	1,212.8	1,412.2	
4.	Other Income	198.5	202.5	190.3	613.0	560.3	840.1	
5.	Profit from Ordinary Activities before Finance Costs	421.4	584.0	561.2	1,402.4	1,773.1	2,252.3	
6.	Finance Costs	4.6	0.4	0.6	5.8	3.2	5.4	
7.	Profit from Ordinary Activities before Tax	416.8	583.6	560.6	1,396.6	1,769.9	2,246.9	
8.	Tax Expense (including Deferred Tax)	126.8	190.2	177.1	443.4	578.9	726.7	
9.	Net Profit for the period	290.0	393.4	383.5	953.2	1,191.0	1,520.2	
10.	Paid-up Equity Share Capital (Face Value ` 5 each)	159.8	159.8	159.8	159.8	159.8	159.8	
11.	Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						8,018.9	
12.	Earnings per Share - (of ` 5 each) (not annualised) Basic and Diluted (`)	9.07	12.31	11.99	29.82	37.26	47.56	
PA	RT II Select Information for the	Ouarter and	Nine Months e	nded 31st Dec	combor 2012			
	Select Information for the	3 months	3 months	3 months	9 months	9 months	Year	
	Particulars	ended 31.12.2012	ended 30.9.2012	ended 31.12.2011	ended 31.12.2012	ended 31.12.2011	ended 31.3.2012	
A	PARTICULARS OF SHAREHOLDING							
1.	Public Shareholding - Number of Shares - Percentage of Shareholding	7,535,995 23.58	7,535,995 23.58	7,535,995 23.58	7,535,995 23.58	7,535,995 23.58	7,535,995 23.58	
2.	Promoters and Promoter Group Shareholding (a) Pledged/Encumbered - Number of Shares	-	-	-	-	-	-	
	 Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group) Percentage of Shares (as a % of the total Share 	-	-	-	-	-	-	
	Capital of the company) (b) Non-Encumbered	-	-	-	-	-	-	
	- Number of Shares	24,424,802	24,424,802	24,424,802	24,424,802	24,424,802	24,424,802	
	 Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group) Percentage of Shares (as a % of the total Share 	100.00	100.00	100.00	100.00	100.00	100.00	
	Capital of the company)	76.42	76.42	76.42	76.42	76.42	76.42	

Particulars	3 months ended 31.12.2012	
B INVESTOR COMPLAINTS		
Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unsolved at the end of the quarter	-	

SEGMENT REVENUE, RESULTS AND CAPITAL EMPLOYED

in ` million

	Bestiesters	3 months	3 months	3 months	9 months	9 months	Year
	Particulars	ended	ended	ended	ended	ended	ended
		31.12.2012	30.9.2012	31.12.2011	31.12.2012	31.12.2011	31.3.2012
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Segment Revenue						
	(a) Pharmaceuticals	1,618.2	1,685.4	1,532.5	4,923.5	4,489.2	5,861.1
	(b) Generics	157.1	148.4	142.1	462.8	433.3	573.1
	(c) OTC	323.0	283.7	341.9	805.4	877.8	1,171.1
	(d) Animal Health	237.1	256.8	206.7	713.4	614.0	837.6
	Total Income from Operations (Net)	2,335.4	2,374.3	2,223.2	6,905.1	6,414.3	8,442.9
2	Segment Results						
	(a) Pharmaceuticals	155.8	323.9	333.6	686.2	1,106.1	1,292.3
	(b) Generics	76.8	41.4	57.5	175.1	155.0	190.4
	(c) OTC	57.8	51.2	71.1	107.0	147.0	175.2
	(d) Animal Health	6.1	13.7	14.3	26.6	54.7	74.9
	Total	296.5	430.2	476.5	994.9	1,462.8	1,732.8
	Add/(Less):					_,	-/
	(a) Finance Costs	(4.6)	(0.4)	(0.6)	(5.8)	(3.2)	(5.4)
	(b) Other Unallocable Expenditure	(72.9)	(45.7)	(104.4)	(201.5)	(236.4)	(296.4)
	(c) Other Unallocable Income	197.8	199.5	189.1	609.0	546.7	815.9
	Profit from Ordinary Activities before Tax	416.8	583.6	560.6	1,396.6	1,769.9	2,246.9
3	Capital Employed						
٥.	(Segment Assets less Segment Liabilities)						
	(a) Pharmaceuticals	238.1	470.3	53.9	238.1	53.9	142.4
	(b) Generics	62.3	60.3	56.3	62.3	56.3	42.6
	(c) OTC	(18.7)	27.8	6.1	(18.7)	6.1	(27.3)
	(d) Animal Health	291.8	295.3	240.0	291.8	240.0	254.6
	Total	573.5	853.7	356.3	573.5	356.3	412.3
	Add: Unallocable Corporate Assets less Unallocable	2.3.0		223.3	2.3.5	223.0	
	Corporate Liabilities	8,558.4	7,988.2	7,864.6	8,558.4	7,864.6	7,766.4
	Total Capital Employed	9,131.9	8,841.9	8,220.9	9,131.9	8,220.9	8,178.7
		-,	-,	2,3.5	- 1 1.0	5,==3.5	2,2

Notes:

- 1. The above results were reviewed by the Audit Committee at its meeting held on 23rd January 2013 and approved at the meeting of the Board of Directors held on that date.
- 2. The results for the quarter ended 31st December 2012 have been subjected to limited review by the statutory auditors of the company.
- 3. Figures for the prior periods have been regrouped where necessary.

By Order of the Board

Ranjit Shahani Vice Chairman and Managing Director Mumbai, 23rd January 2013